These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9538169)

  • 21. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
    Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients.
    Guadagni F; Ferroni P; Basili S; Facciolo F; Carlini S; Crecco M; Martini F; Spila A; D'Alessandro R; Aloe S; Cerasoli V; Del Monte G; Mariotti S; Mineo TC; Roselli M
    Lung Cancer; 2004 Jun; 44(3):303-10. PubMed ID: 15140543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
    Han JY; Choi BG; Choi JY; Lee SY; Ju SY
    Lung Cancer; 2006 Nov; 54(2):227-34. PubMed ID: 16935391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy.
    Naumnik W; Chyczewska E; Ossolinska M
    Cancer Invest; 2009 Aug; 27(7):741-6. PubMed ID: 19340656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer.
    Ujiie H; Tomida M; Akiyama H; Nakajima Y; Okada D; Yoshino N; Takiguchi Y; Tanzawa H
    Anticancer Res; 2012 Aug; 32(8):3251-8. PubMed ID: 22843899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
    Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).
    Srimuninnimit V; Ariyapanya S; Nimmannit A; Wonglaksanapimon S; Akewanlop C; Soparattanapaisarn N
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S199-207. PubMed ID: 22574550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
    Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
    Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma.
    Oka M; Yamamoto K; Takahashi M; Hakozaki M; Abe T; Iizuka N; Hazama S; Hirazawa K; Hayashi H; Tangoku A; Hirose K; Ishihara T; Suzuki T
    Cancer Res; 1996 Jun; 56(12):2776-80. PubMed ID: 8665513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
    Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
    Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
    Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
    Orditura M; Romano C; De Vita F; Galizia G; Lieto E; Infusino S; De Cataldis G; Catalano G
    Cancer Immunol Immunother; 2000 Dec; 49(10):530-6. PubMed ID: 11129323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.
    Shang GH; Jia CQ; Tian H; Xiao W; Li Y; Wang AH; Dong L; Lin DJ
    Respir Med; 2009 Dec; 103(12):1949-53. PubMed ID: 19535236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum cytokines and tumour markers in patients with non-small cell carcinoma of the lung.
    Bansal AS; Bruce J; Devine PL; Scells B; Zimmermann PV
    Dis Markers; 1997 Nov; 13(3):195-9. PubMed ID: 9405932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dry extract of Scutellaria baicalensis as a hemostimulant in antineoplastic chemotherapy in patents with lung cancer].
    Gol'dberg VE; Ryzhakov VM; Matiash MG; Stepovaia EA; Boldyshev DA; Litvinenko VI; Dygaĭ AM
    Eksp Klin Farmakol; 1997; 60(6):28-30. PubMed ID: 9460593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer.
    Xu C; Hao K; Yu L; Zhang X
    Biomarkers; 2014 Jun; 19(4):287-90. PubMed ID: 24731052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.